Detalhe da pesquisa
1.
Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Monkeys and Translational Modeling for Selection of Dose and Frequency in Clinical Trials.
J Pharmacol Exp Ther
; 378(3): 207-214, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34210753
2.
A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition.
J Pharmacol Exp Ther
; 373(2): 184-192, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32098861
3.
Response to Comments on "Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Monkeys and Translational Modeling for Selection of Dose and Frequency in Clinical Trials".
J Pharmacol Exp Ther
; 383(3): 248-249, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36368904
4.
Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.
J Pharmacokinet Pharmacodyn
; 44(3): 179-191, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28132162
5.
A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
J Pharmacol Exp Ther
; 341(3): 702-8, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22414855
6.
Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.
J Clin Pharmacol
; 62(5): 594-608, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34783362
7.
Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
J Pharmacol Exp Ther
; 331(2): 627-35, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19690190
8.
Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
J Clin Pharmacol
; 57(8): 1031-1041, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28369979
9.
A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.
Cancer Chemother Pharmacol
; 78(4): 697-708, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27491482
10.
Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.
AAPS J
; 15(2): 551-8, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23408094
11.
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
J Clin Oncol
; 31(5): 573-83, 2013 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23295790
12.
P-glycoprotein induction and tumor cell-kill dynamics in response to differential doxorubicin dosing strategies: a theoretical pharmacodynamic model.
Pharm Res
; 22(5): 710-5, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15906164